Nanjing Sanhome Pharmaceutical Co., Ltd.
Clinical trials sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot SH009 targets tough cancers in early trial Results expected Dec 2026 (estimated)
- New drug SH006 tested in patients with advanced solid tumors Results expected Dec 2026 (estimated)
- New pill combo aims to fight Hard-to-Treat breast cancer Results expected Jun 2027 (estimated)
-
New pill combo aims to fight Hard-to-Treat breast cancer
Disease control OngoingThis early-phase trial tests a new oral drug, SH3765, combined with the injectable hormone therapy fulvestrant in 30 women with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The main goals are to check safety, find the best dose, and see if the combina…
Phase 1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug SH006 tested in patients with advanced solid tumors
Disease control OngoingThis early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…
Phase 1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC